MONTREAL, CANADA--(Marketwired - Feb. 28, 2014) - Knight Therapeutics Inc. (TSX VENTURE:GUD) ("Knight") announced today that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans. Mr. Kadanoff holds a B. Eng. with Distinction in Chemical Engineering and a Minor in Management from McGill University, and an M.B.A. with Distinction from INSEAD.<br /><br />About Knight Therapeutics Inc.:<br /><br />Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares are expected to begin trading on the TSX-V on March 3, 2014 under the symbol GUD.